Creo Medical Group PLC UK Endoscopy Training Course
October 17 2019 - 2:00AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
17 October 2019
Creo Medical Group plc
("Creo" or the "Company")
UK Endoscopy Training Course
Live demonstrations and training using Creo's Speedboat and
CROMA platform
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
Queen Elizabeth The Queen Mother Hospital in Margate ("QEQM
Hospital"), part of the East Kent Hospitals University NHS
Foundation Trust ("East Kent Trust"), today hosts its third
endoscopy training course. The three-day training course will
include live demonstrations and hands-on stations training on
Creo's Speedboat device.
The Course convenor is Dr Zacharias Tsiamoulos, Consultant in
Gastroenterology and Specialist in GI Endoscopy at the East Kent
Trust. Dr Tsiamoulos is a key opinion leader in the field of
Gastrointestinal ("GI") therapeutic endoscopy and a leading user of
Speedboat for colorectal endoscopic submucosal dissection, an
advanced surgical procedure using endoscopy to remove
gastrointestinal pre-cancerous lesions that have not entered the
muscle layer.
A number of the International and National Faculty participants
have already been trained on Speedboat through the Company's
Clinical Education Programme. These first adopters, as well as
other clinicians from multiple international jurisdictions,
including Norio Fukami, Professor of Gastroenterology at the Mayo
Clinic, Arizona (US), will be able to share their expertise and
experience with the East Kent Trust delegates. The full programme
and list of attendees are available through the following link:
https://meded.ekhuft.nhs.uk/resources/kent2019
About Speedboat and CROMA
Speedboat is the first in a range of endoscopic minimally
invasive surgical devices to be cleared for use with the Company's
CROMA Advanced Energy platform, which uniquely combines bipolar
radiofrequency energy for precise tissue dissection along with
microwave energy for highly controlled coagulation and tissue
ablation. A growing number of GI Endoscopists in the UK, South
Africa, Mainland Europe and the US have now performed multiple
successful treatments using Speedboat, removing lesions in both
upper and lower GI cases.
Typically, instead of having to undergo surgery under general
anaesthetic, these patients only needed sedation and were treated
as day patients. As a result, Speedboat helps to reduce the risks
associated with alternative open, laparoscopic and existing
endoscopic procedures, reducing the length of stay in hospital for
the patient and the cost of treatment by transferring therapy from
the operating theatre to the endoscopy room.
Craig Gulliford, Chief Executive Officer of Creo, commented: "We
are extremely proud that the third Kent Course is underway and will
include demonstrations and lectures on the use of Speedboat. In
time we expect this to help expand the list of physicians capable
of carrying out procedures using our technology. It is paramount
that each clinician is mentored and given the best training so they
can deliver consistently accurate procedures for the patients and
ensure that surgical endoscopy using Creo's technology is safely
adopted worldwide."
Creo Medical Group plc +44 (0)129 160 6005
Richard Rees (CFO)
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Lianne Cawthorne Mob: +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiofrequency energy to surgical endoscopy.
Creo has developed CROMA, an electrosurgical advanced energy
platform that combines bipolar RF for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
platform to market through a suite of medical devices which the
Company has designed, initially for the emerging field of GI
therapeutic endoscopy, an area with high unmet needs. The CROMA
Advanced Energy platform will be developed further for bronchoscopy
and laparoscopy procedures. The Company believes that its
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABIBDGGBBBGCL
(END) Dow Jones Newswires
October 17, 2019 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024